Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603870 | 0.88 | PARP1 (0.41) | PARP1HTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL4950313 | 0.86 | PARP1 (0.40) | PARP1HTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL13738797 | 0.75 | SSTR4 (0.41) | — | |
| SCHEMBL16127651 | 0.74 | PARP1 (0.52) | PARP1HTR2AHTR2CADRA1ASLC6A2 | |
| SCHEMBL5542419 | 0.74 | PARP1 (0.56) | PARP1HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL293877 | 0.74 | PARP1 (0.52) | PARP1HTR2AHTR2CADRA1ASLC6A2 | |
| SCHEMBL30363808 | 0.74 | PARP1 (0.52) | PARP1HTR2AHTR2CADRA1ASLC6A2 | |
| SCHEMBL13651166 | 0.74 | PARP1 (0.52) | PARP1HTR2AHTR2CADRA1ASLC6A2 | |
| SCHEMBL2007697 | 0.74 | PARP1 (0.52) | PARP1HTR2CADRA2AADRA2BADRA2C | |
| SCHEMBL29791283 | 0.74 | PARP1 (0.52) | PARP1HTR2AHTR2CADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| EP-4729516-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4698524-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | Alceptor Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260042769-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | ALCEPTOR THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| EP-4678640-A1 | AROMATIC AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-12435054-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025111414-A1 | TRPM3-MODULATING BENZOFURAN DERIVATIVES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-05-30 | — | — | WO | disclosed |
| EP-1463501-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6617346-B1 | Inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity | HOFFMANN-LA ROCHE INC. | 2003-09-09 | — | — | US | disclosed |
| WO-2003051360-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0906912-B1 | Indanol derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6060487-A | Indanol compounds | ADIR ET COMPAGNIE (FR) | 2000-05-09 | — | — | US | disclosed |
| US-5958927-A | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 1999-09-28 | — | — | US | disclosed |
| CN-1218051-A | New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-06-02 | — | — | CN | disclosed |
| EP-0906912-A1 | Indanol derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | PARP1 3692/4885HTR2A 1496/4885HTR2C 656/4885 |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | PARP1 3281/4885HTR2A 2799/4885HTR2C 2342/4885 |
| US-12435054-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | PARP1 1133/4885HTR2A 3742/4885HTR2C 3397/4885 |
| US-20260042769-A1 | TRIARYL AGONISTS OF ALPHA-2 ADRENERGIC RECEPTORS | ADRB2, ADRB1, ADRB3 | PARP1 3836/4885HTR2A 155/4885HTR2C 72/4885 |
| US-12435060-B2 | Acylamino bridged heterocyclic compound, and composition and application thereof | RIPK1, RIPK3, RIPK4 | PARP1 632/4885HTR2A 4631/4885HTR2C 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.